Natera Submits Signatera™ CDx PMA to FDA

Core Viewpoint - Natera, Inc. has submitted a premarket approval (PMA) application to the U.S. FDA for its Signatera™ CDx, aimed at detecting molecular residual disease (MRD) in muscle-invasive bladder cancer (MIBC) patients who may benefit from atezolizumab treatment [1] Company Summary - Natera, Inc. is recognized as a global leader in cell-free DNA and precision medicine [1] - The PMA submission is backed by data from a randomized, double-blind, phase 3 clinical trial known as IMvi [1]